Unknown

Dataset Information

0

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.


ABSTRACT: Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer cases, and almost half of newly diagnosed patients have metastatic disease. Pemetrexed is a widely used drug for NSCLC and inhibits several folate-dependent enzymes including thymidylate synthase (TS). Increased expression of TS confers resistance to pemetrexed in vitro and predicts poor response to pemetrexed. Rapamycin is an mTOR inhibitor and suppresses cap-dependent synthesis of specific mRNA species. Here, we show that the combination of rapamycin and pemetrexed synergistically inhibits proliferation of NSCLC cells. Although pemetrexed as a single agent induced TS, pretreatment with rapamycin suppressed pemetrexed-induced TS expression. In vivo, the combination of rapamycin and pemetrexed inhibited growth of NSCLC xenografts, which correlated with decreased mTOR activity and suppression of pemetrexed-induced TS expression. The ability of rapamycin to enhance the efficacy of pemetrexed and prevent TS expression has implications for the design of Phase I and/or Phase II NSCLC clinical trials with mTOR inhibitors in combination with pemetrexed.

PROVIDER: S-EPMC4011583 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5421841 | BioStudies
| S-EPMC4147343 | BioStudies
| S-EPMC4437388 | BioStudies
| S-EPMC3645936 | BioStudies
| S-EPMC4871516 | BioStudies
| S-EPMC4198757 | BioStudies
| S-EPMC7255002 | BioStudies
| S-EPMC6605998 | BioStudies
| S-EPMC3629022 | BioStudies
| S-EPMC7463866 | BioStudies